Alternatively, CD63, the prolactin receptor, and amyloid beta precursor-like protein 2 are selected as promising candidate receptors for discovering novel bsADC drugs dual-targeting HER2; they would have been taken into therapeutic consideration for HER2-positive breast cancer if they bore the capacity to cover single-target combined therapy [94,95,96]. The gene discussed is ERBB2; the disease is breast carcinoma.